 | Up a level |
2023
Koschmieder, Steffen 
ORCID: 0000-0002-1011-8171, Isfort, Susanne, Wolf, Dominik, Heidel, Florian H., Hochhaus, Andreas, Schafhausen, Philippe, Griesshammer, Martin, Wolleschak, Denise, Platzbecker, Uwe, Doehner, Konstanze, Jost, Philipp J., Parmentier, Stefani, Schaich, Markus, von Bubnoff, Nikolas, Stegelmann, Frank, Maurer, Angela, Crysandt, Martina, Gezer, Deniz, Kortmann, Maike, Franklin, Jeremy, Frank, Julia, Hellmich, Martin and Bruemmendorf, Tim H.
(2023).
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Ann. Hematol., 102 (2).
S. 349 - 359.
NEW YORK:
SPRINGER.
ISSN 1432-0584
2022
Koschmieder, Steffen, Isfort, Susanne, Heidel, Florian H., Hochhaus, Andreas, Becker, Heiko, Jost, Philipp J., Schafhausen, Philippe, Griesshammer, Martin, Wolleschak, Denise, Haenel, Mathias, Goethert, Joachim R., Teichmann, Lino L., Sockel, Katja, Radsak, Markus P., Reiter, Andreas, Doehner, Konstanze, Balleisen, Sebastian, Jaekel, Nadja, von Bubnoff, Nikolas, Stegelmann, Frank, Gezer, Deniz, Kortmann, Maike, Frank, Julia, Hellmich, Martin and Bruemmendorf, Tim H. (2022). Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Blood, 140. S. 1790 - 1794. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020